ChemPartner PharmaTech Co Ltd: Market Overview and Performance

On May 30, 2025, the A-share market experienced a downturn, with the Shanghai Composite Index (Shanghai Index) falling by 0.47%, the Shenzhen Component Index by 0.85%, and the ChiNext Index by 0.96%. Despite the overall market decline, certain sectors and stocks showed resilience and even growth. Notably, the biotechnology sector, particularly companies involved in innovative drug concepts, saw significant gains.

ChemPartner PharmaTech Co Ltd Fundamentals

  • Asset Type: Company
  • Sector: Health Care
  • Industry: Biotechnology
  • Primary Exchange: Shenzhen Stock Exchange
  • Currency: CNY
  • Close Price (2025-05-27): 7.13 CNY
  • 52 Weeks High (2024-12-09): 9.86 CNY
  • 52 Weeks Low (2024-07-08): 3.7 CNY
  • Market Cap: 3,162,071,352 CNY

ChemPartner PharmaTech Co Ltd specializes in the research, development, production, and sale of prebiotic products globally. The company focuses on digestive microbiota health products, offering fructooligosaccharides under the EUOLIGO brand and galactooligosaccharides under the GOSYAN brand. These products are used in various infant and young children’s foods, milk powders, general foods, and health foods.

Market Performance and Trends

Despite the general market downturn, the innovative drug concept stocks performed exceptionally well. Stocks like RuiZhi Pharmaceutical, Hainan Haiyao, and Ha Sanlian saw significant gains, with some reaching their daily price limits. The biotechnology sector, particularly innovative drug stocks, was a standout performer, with RuiZhi Pharmaceutical achieving a four-day consecutive price limit increase.

Banking Sector Strength

The banking sector continued to show strength, with Hangzhou Bank and Chengdu Bank reaching historical highs. This trend indicates a robust performance in the financial sector, contrasting with the broader market’s decline.

Conclusion

While the A-share market faced a downturn on May 30, 2025, certain sectors like biotechnology and banking demonstrated resilience and growth. ChemPartner PharmaTech Co Ltd, with its focus on prebiotic products, remains a key player in the biotechnology sector. The company’s performance and market trends will be closely watched by investors in the coming days.